Losartan Potassium Tablet, Film Coated
Product Images NDC 67296-2225

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 67296-2225). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartanpotassiumfigure1 (Losartanpotassiumfigure1)

This text provides information on the comparison between Atenolol and Losartan potassium in terms of the percentage of patients with the primary endpoint. It shows an adjusted risk reduction of 13% with a significance level of p=0.021. The study spans over 66 months and visualizes the data points at different time intervals.*

FDA Label Image

Losartanpotassiumfigure2 (Losartanpotassiumfigure2)

This text shows data related to the percentage of patients experiencing fatal/non-fatal stroke over a period of time in a study. The study appears to involve the drugs Atenolol and Losartan potassium.*

FDA Label Image

Losartanpotassiumfigure3 (Losartanpotassiumfigure3)

This document provides an overview of results from a study comparing the effects of Losartan Potassium and Atenolol on a primary composite outcome. The study analyzed data based on different factors such as age (<65 years, >65 years), gender (female), diabetes status (yes, no), and history of cardiovascular disease (yes, no). The results include event rates and hazard ratios for stroke (fatal/non-fatal) between the two medications. The findings suggest a potential preference for Losartan Potassium over Atenolol in relation to the primary composite outcome.*

FDA Label Image

Losartanpotassiumfigure4 (Losartanpotassiumfigure4)

This text provides information on the percentage of patients with an event in a study comparing Losartan Potassium and Placebo. It states that there was a risk reduction of 16.1% with a p-value of 0.022.*

FDA Label Image

Losartanpotassiumlabel100mg90s (Losartanpotassiumlabel100mg90s)

Each film coated tablet contains 100 mg of losartan potassium USP. The usual adult dosage information can be found in the package insert. It is recommended to store the medication at 20°C to 25°C (68°F to 77°F) and to keep the container tightly closed and protected from light. A warning is given to keep the medication away from children. The tablets are manufactured by Hetero Labs Limited in India and distributed by Northstar Rx LLC in Memphis, TN. The product is labeled as Losartan Potassium Tablets USP, containing 90 tablets per container.*

FDA Label Image

Losartanpotassiumlabel25mg90s (Losartanpotassiumlabel25mg90s)

Each film-coated tablet contains 25 mg of losartan potassium USP. The usual adult dosage information is available in the package insert. It is important to keep the tablets at controlled room temperature and store them in a tightly closed container away from light. This medication should be kept out of reach of children.The tablets are manufactured for Northstar Rx LLC and produced by Hetero Labs Limited in India.*

FDA Label Image

Losartanpotassiumlabel50mg90s (Losartanpotassiumlabel50mg90s)

This is a description of the medication Losartan Potassium Tablets USP, each containing 50 mg of losartan potassium. The usual adult dosage information can be found in the package insert. It is advised to store the tablets at a temperature of 20°C to 25°C and to keep the container tightly closed and protected from light. There is a warning to keep the medication out of the reach of children. The tablets are manufactured by Hetero Labs Limited in India for Northstar Rx LLC in Memphis, TN.*

FDA Label Image

Losartanpotassiumstructure (Losartanpotassiumstructure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.